BioCentury | Mar 1, 2019
Financial News

After J&J retinal dea, MeiraGTx raises $80M for partnered programs

...worldwide rights to three of its rare inherited retinal disease gene therapies: AAV-RPGR, AAV-CNGB3 and AAV-CNGA3...
BioCentury | Feb 27, 2019
Financial News

After J&J retinal deal, MeiraGTx raises $80M for unpartnered programs

...worldwide rights to three of its rare inherited retinal disease gene therapies: AAV-RPGR, AAV-CNGB3 and AAV-CNGA3...
...Perceptive Advisors, OrbiMed Advisors and 683 Capital Management also participated in the placement. Elizabeth S. Eaton AAV-AQP1 (A00X) AAV-CNGA3...
BioCentury | Jan 31, 2019
Company News

J&J, MeiraGTx partner on gene therapies for rare retinal diseases

...delivers the CNGB3 gene and is in Phase I/II testing, and AAV-CNGA3, which delivers the CNGA3...
...a partnership with University of Pennsylvania to develop AAV vectors to deliver Alzheimer's disease antibodies. CNGA3...
...channel β3; RPE65 - Retinal pigment epithelium-specific protein 65kDa; RPGR - Retinitis pigmentosa GTPase regulator Mark Zipkin AAV-CNGA3...
BioCentury | Dec 14, 2018
Company News

Biogen returns gene therapies to AGTC on lack of clinical activity

...XLRP and one each in its wholly owned gene therapy programs for CNGB3 achromatopsia and CNGA3...
BioCentury | Dec 13, 2018
Company News

Biogen returns gene therapies to AGTC on lack of clinical activity

...XLRP and one each in its wholly owned gene therapy programs for CNGB3 achromatopsia and CNGA3...
Items per page:
1 - 5 of 5